1. HBW Insight

FDA Raps Supplement Maker Marco Pharma For GMP Violations Surfaced During Inspection

 
• By Eileen Francis

The US Food and Drug Administration directs Marco Pharma International to correct GMP compliance issues identified during a May 2019 site inspection, including quality control and recordkeeping failures, in a warning letter made public 4 February.

WarningSign_1200x675

Marco Pharma International LLC evidently has struggled to address issues identified during an inspection of its Roseburg, OR manufacturing facility, based on an FDA warning letter published on 4 February.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation